Ursodeoxycholic acid for COVID-19: real-time meta analysis of 19 studies
Abstract
Significantly lower risk is seen for progression, recovery, and cases. 12 studies from 11 independent teams in 4 countries show significant
benefit.
Meta analysis using the most serious outcome reported shows
20% [-2‑38%] lower risk, without reaching statistical significance. Results are similar for higher quality and peer-reviewed studies.
No treatment is 100%
effective. Protocols combine safe and effective options with individual
risk/benefit analysis and monitoring.
Other treatments are more effective.
UDCA currently has no early treatment studies.
All data and sources to reproduce this analysis are in the appendix.
Yu et al. present another meta analysis for ursodeoxycholic acid, showing significant improvement for severity.
Ursodeoxycholic acid for COVID-19 — Highlights
UDCA reduces
risk with very high confidence for recovery and cases, and low confidence for hospitalization, progression, and in pooled analysis.
Real-time updates
and corrections with a consistent protocol for 112 treatments. Outcome specific analysis and combined evidence from all
studies including treatment delay, a primary confounding factor.
Figure 1.
A. Random effects
meta-analysis. This plot shows pooled effects,
see the specific outcome analyses for individual outcomes.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Effect extraction is pre-specified, using the most serious outcome reported.
For details see the appendix.
B. Timeline of results in ursodeoxycholic acid studies.
SARS-CoV-2 infection primarily begins in the upper respiratory
tract and may progress to the lower respiratory tract, other tissues, and the
nervous and cardiovascular systems, which may lead to cytokine storm,
pneumonia, ARDS, neurological injury2-13 and
cognitive deficits5,10, cardiovascular
complications14-17, organ failure, and death.
Minimizing replication as early as possible is recommended.
SARS-CoV-2 infection and replication involves the complex interplay of 50+
host and viral proteins and other factorsA,18-24, providing many
therapeutic targets for which many existing compounds have known activity.
Scientists have predicted that over 8,000 compounds may
reduce COVID-19 risk25, either by
directly minimizing infection or replication, by supporting immune system
function, or by minimizing secondary complications.
Ursodeoxycholic acid reduced ACE2 expression and blocked pseudovirus
infection in Calu-3 cells26, protected against Omicron infection in hamsters by
downregulating ACE2 expression via FXR inhibition, leading to reduced
viral load in the upper respiratory tract and prevention of weight
loss27, and inhibited SARS-CoV-2 infection by downregulating
ACE2 expression via FXR inhibition in multiple tissues (respiratory,
biliary, and intestinal), reduced viral transmission in a hamster model,
and decreased viral replication in human organ perfusion models28.
We analyze all significant
controlled studies of
ursodeoxycholic acid
for COVID-19.
Search methods, inclusion criteria, effect extraction criteria (more serious
outcomes have priority), all individual study data, PRISMA answers, and
statistical methods are detailed in Appendix 1. We present random
effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, peer-reviewed studies, and higher quality studies.
Figure 2 shows stages of possible treatment for
COVID-19. Prophylaxis refers to regularly taking medication before
becoming sick, in order to prevent or minimize infection. Early
Treatment refers to treatment immediately or soon after symptoms appear,
while Late Treatment refers to more delayed treatment.
Figure 2. Treatment stages.
Ursodeoxycholic acid reduced ACE2 expression and blocked pseudovirus
infection in Calu-3 cells26, protected against Omicron infection in hamsters by
downregulating ACE2 expression via FXR inhibition, leading to reduced
viral load in the upper respiratory tract and prevention of weight
loss27, and inhibited SARS-CoV-2 infection by downregulating
ACE2 expression via FXR inhibition in multiple tissues (respiratory,
biliary, and intestinal), reduced viral transmission in a hamster model,
and decreased viral replication in human organ perfusion models28.
An In Vivo animal study supports the efficacy of ursodeoxycholic acid27.
Preclinical research is an important part of the development of
treatments, however results may be very different in clinical trials.
Preclinical results are not used in this paper.
Table 1 summarizes the results for all stages combined, for peer-reviewed studies, after exclusions, and for specific outcomes.
Table 2 shows results by treatment stage.
Figure 3 plots individual results by treatment stage.
Figure 4, 5, 6, 7, 8, 9, 10, 11, and 12
show forest plots for random effects meta-analysis of
all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, recovery, cases, and peer reviewed studies.
| Improvement | Studies | Patients | Authors | |
|---|---|---|---|---|
| All studies | 20% [-2‑38%] | 19 | 43,512 | 238 |
| After exclusions | 18% [9‑26%] *** | 18 | 43,512 | 235 |
| Peer-reviewed studiesPeer-reviewed | 19% [-5‑38%] | 18 | 43,405 | 227 |
| Mortality | 16% [-14‑39%] | 7 | 27,008 | 144 |
| ICU admissionICU | 27% [-52‑65%] | 3 | 11,693 | 96 |
| HospitalizationHosp. | 17% [-4‑34%] | 5 | 23,448 | 120 |
| Recovery | 41% [22‑56%] *** | 3 | 417 | 28 |
| Cases | 16% [9‑22%] **** | 11 | 13,648 | 94 |
| Late treatment | Prophylaxis | |
|---|---|---|
| All studies | 39% [1‑62%] * | 19% [-5‑38%] |
| After exclusions | 39% [1‑62%] * | 17% [7‑25%] *** |
| Peer-reviewed studiesPeer-reviewed | 39% [1‑62%] * | 18% [-7‑37%] |
| Mortality | 16% [-14‑39%] | |
| ICU admissionICU | 27% [-52‑65%] | |
| HospitalizationHosp. | 17% [-4‑34%] | |
| Recovery | 39% [1‑62%] * | 43% [18‑60%] ** |
| Cases | 16% [9‑22%] **** |
Loading..
Figure 3. Scatter plot showing the most serious outcome in all studies, and for studies within each stage. Diamonds shows the results of random effects meta-analysis.
Loading..
Loading..
Figure 4. Random effects meta-analysis for all studies.
This plot shows pooled effects,
see the specific outcome analyses for individual outcomes.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Effect extraction is pre-specified, using the most serious outcome reported.
For details see the appendix.
Loading..
Loading..
Figure 5. Random effects meta-analysis for mortality results.
Loading..
Figure 6. Random effects meta-analysis for ventilation.
Loading..
Figure 7. Random effects meta-analysis for ICU admission.
Loading..
Figure 8. Random effects meta-analysis for hospitalization.
Loading..
Figure 9. Random effects meta-analysis for progression.
Loading..
Figure 10. Random effects meta-analysis for recovery.
Loading..
Figure 11. Random effects meta-analysis for cases.
Loading..
Figure 12. Random effects meta-analysis for peer reviewed studies.
Effect extraction is pre-specified, using the most serious outcome reported,
see the appendix for details.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Zeraatkar et al. analyze 356 COVID-19 trials, finding no significant
evidence that preprint results are inconsistent with peer-reviewed studies.
They also show extremely long peer-review delays, with a median of 6 months to
journal publication. A six month delay was equivalent to around 1.5 million
deaths during the first two years of the pandemic. Authors recommend using
preprint evidence, with appropriate checks for potential falsified data, which
provides higher certainty much earlier. Davidson et al. also showed no
important difference between meta analysis results of preprints and
peer-reviewed publications for COVID-19, based on 37 meta analyses including
114 trials.
To avoid bias in the selection of studies, we analyze all
non-retracted studies. Here we show the results after excluding
studies with major issues likely to alter results, non-standard studies, and
studies where very minimal detail is currently available. Our bias evaluation
is based on analysis of each study and identifying when there is a significant
chance that limitations will substantially change the outcome of the study. We
believe this can be more valuable than checklist-based approaches such as
Cochrane GRADE, which can be easily influenced by potential bias, may ignore
or underemphasize serious issues not captured in the checklists, and may
overemphasize issues unlikely to alter outcomes in specific cases (for example
certain specifics of randomization with a very large effect size and
well-matched baseline characteristics).
The studies excluded are as below.
Figure 13 shows a forest plot for random
effects meta-analysis of all studies after exclusions.
Sakamaki, significant unadjusted confounding possible.
Loading..
Figure 13. Random effects meta-analysis for all studies after exclusions.
This plot shows pooled effects,
see the specific outcome analyses for individual outcomes.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Effect extraction is pre-specified, using the most serious outcome reported.
For details see the appendix.
Heterogeneity in COVID-19 studies arises from many factors including:
The time between infection or the onset of symptoms and
treatment may critically affect how well a treatment works. For example an
antiviral may be very effective when used early but may not be effective in
late stage disease, and may even be harmful. Oseltamivir, for example, is
generally only considered effective for influenza when used within 0-36 or
0-48 hours32,33. Baloxavir marboxil studies for influenza
also show that treatment delay is critical — Ikematsu et al. report
an 86% reduction in cases for post-exposure prophylaxis, Hayden et al.
show a 33 hour reduction in the time to alleviation of symptoms for treatment
within 24 hours and a reduction of 13 hours for treatment within 24-48 hours,
and Kumar et al. report only 2.5 hours improvement for inpatient
treatment.
| Treatment delay | Result |
| Post-exposure prophylaxis | 86% fewer cases34 |
| <24 hours | -33 hours symptoms35 |
| 24-48 hours | -13 hours symptoms35 |
| Inpatients | -2.5 hours to improvement36 |
Figure 14 shows a mixed-effects meta-regression for efficacy
as a function of treatment delay in COVID-19 studies from 112 treatments, showing
that efficacy declines rapidly with treatment delay. Early treatment is
critical for COVID-19.
Loading..
Figure 14. Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 112 treatments.
Details of the patient population including age and comorbidities may
critically affect how well a treatment works. For example, many COVID-19
studies with relatively young low-comorbidity patients show all patients
recovering quickly with or without treatment. In such cases, there is little
room for an effective treatment to improve results, for example as in
López-Medina et al.
Efficacy may depend critically on the distribution of
SARS-CoV-2 variants encountered by patients. Risk varies significantly across
variants38, for example the Gamma variant shows significantly
different characteristics39-42. Different
mechanisms of action may be more or less effective depending on variants, for
example the degree to which TMPRSS2 contributes to viral entry can differ
across variants43,44.
Effectiveness may depend strongly on the dosage and treatment regimen.
The quality of medications may vary significantly between
manufacturers and production batches, which may significantly affect efficacy
and safety. Williams et al. analyze ivermectin from 11 different sources,
showing highly variable antiparasitic efficacy across different manufacturers.
Xu et al. analyze a treatment from two different manufacturers, showing 9
different impurities, with significantly different concentrations for each
manufacturer.
Across all
studies there is a strong association between different outcomes, for example
improved recovery is strongly associated with lower mortality. However,
efficacy may differ depending on the effect measured, for example a treatment
may be more effective against secondary complications and have minimal effect
on viral clearance.
The
distribution of studies will alter the outcome of a meta analysis. Consider a
simplified example where everything is equal except for the treatment delay,
and effectiveness decreases to zero or below with increasing delay. If there
are many studies using very late treatment, the outcome may be negative, even
though early treatment is very effective.
All meta analyses combine heterogeneous studies, varying in population,
variants, and potentially all factors above, and therefore may obscure
efficacy by including studies where treatment is less effective. Generally, we
expect the estimated effect size from meta analysis to be less than that for
the optimal case.
Looking at all studies is valuable for providing an overview of all research,
important to avoid cherry-picking, and informative when a positive result is
found despite combining less-optimal situations. However, the resulting
estimate does not apply to specific cases such as
early treatment in high-risk populations.
While we present results for all studies, we also present treatment time and
individual outcome analyses, which may be more informative for specific use
cases.
For COVID-19, delay in clinical results translates into
additional death and morbidity, as well as additional economic and societal
damage. Combining the results of studies reporting different outcomes is
required.
There may be no mortality in a trial with low-risk patients,
however a reduction in severity or improved viral clearance may translate
into lower mortality in a high-risk population.
Different studies may report lower severity, improved recovery, and lower mortality,
and the significance may be very high when combining the results.
"The studies reported different outcomes" is not a good reason for
disregarding results.
Pooling the results of studies reporting different outcomes allows us to use
more of the available information. Logically we should, and do, use additional
information when evaluating treatments—for example dose-response and
treatment delay-response relationships provide additional evidence of efficacy
that is considered when reviewing the evidence for a treatment.
We present both specific outcome and pooled analyses.
In order to combine the results of studies reporting different outcomes we use
the most serious outcome reported in each study, based on the thesis that
improvement in the most serious outcome provides comparable measures of
efficacy for a treatment. A critical advantage of this approach is
simplicity and transparency.
There are many other ways to combine evidence for different outcomes, along
with additional evidence such as dose-response relationships, however these
increase complexity.
Trials with high-risk patients may be restricted due to ethics for treatments
that are known or expected to be effective, and they increase difficulty for
recruiting. Using less severe outcomes as a proxy for more serious outcomes
allows faster and safer collection of evidence.
For many COVID-19 treatments, a reduction in mortality logically
follows from a reduction in hospitalization, which follows from a reduction in
symptomatic cases, which follows from a reduction in PCR positivity. We can
directly test this for COVID-19.
Analysis of the the association between different outcomes across studies from
all 112
treatments we cover confirms the validity of pooled outcome analysis for COVID-19.
Figure 15 shows that lower hospitalization is very strongly associated
with lower mortality (p < 0.000000000001).
Similarly, Figure 16 shows that improved recovery is very strongly associated
with lower mortality (p < 0.000000000001).
Considering the extremes, Singh et al. show an association between viral clearance and
hospitalization or death, with p = 0.003 after excluding one large
outlier from a mutagenic treatment, and based on 44 RCTs including 52,384
patients.
Figure 17 shows that improved viral clearance is strongly associated
with fewer serious outcomes. The association is very similar to
Singh et al., with higher confidence due to the larger number of
studies. As with Singh et al., the confidence increases
when excluding the outlier treatment, from p = 0.00000032 to p = 0.000000011.
Loading..
Figure 15. Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.
Loading..
Figure 16. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.
Loading..
Figure 15. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.
Currently, 48 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. 89% of these have been confirmed with one or more specific outcomes, with a mean delay of 5.0 months. When restricting to RCTs only, 56% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 6.4 months.
Figure 18 shows when treatments were found effective during the
pandemic. Pooled outcomes often resulted in earlier detection of efficacy.
Loading..
Loading..
Figure 18. The time when studies showed that
treatments were effective, defined as statistically significant improvement of
≥10% from ≥3 studies.
Pooled results typically show efficacy earlier than specific
outcome results. Results from all studies often shows efficacy much earlier
than when restricting to RCTs.
Results reflect conditions as used in trials to date, these depend on the
population treated, treatment delay, and treatment regimen.
Pooled analysis could hide efficacy, for example a treatment that is
beneficial for late stage patients but has no effect on viral clearance may
show no efficacy if most studies only examine viral clearance. In practice, it
is rare for a non-antiviral treatment to report viral clearance and to not
report clinical outcomes; and in practice other sources of heterogeneity such
as difference in treatment delay is more likely to hide efficacy.
Analysis validates the use of pooled effects and shows significantly faster
detection of efficacy on average.
However, as with all meta analyses, it is important to review the different
studies included. We also present individual outcome analyses, which may be
more informative for specific use cases.
Publishing is often biased
towards positive results, however evidence suggests that there may be a negative bias for
inexpensive treatments for COVID-19. Both negative and positive results are
very important for COVID-19, media in many countries prioritizes negative
results for inexpensive treatments (inverting the typical incentive for
scientists that value media recognition), and there are many reports of
difficulty publishing positive results60-63.
For ursodeoxycholic acid, there is currently not
enough data to evaluate publication bias with high confidence.
Funnel
plots have traditionally been used for analyzing publication bias. This is
invalid for COVID-19 acute treatment trials — the underlying assumptions
are invalid, which we can demonstrate with a simple example. Consider a set of
hypothetical perfect trials with no bias. Figure 19 plot A
shows a funnel plot for a simulation of 80 perfect trials, with random group
sizes, and each patient's outcome randomly sampled (10% control event
probability, and a 30% effect size for treatment). Analysis shows no asymmetry
(p > 0.05). In plot B, we add a single typical variation in COVID-19 treatment
trials — treatment delay. Consider that efficacy varies from 90% for
treatment within 24 hours, reducing to 10% when treatment is delayed 3 days.
In plot B, each trial's treatment delay is randomly selected. Analysis now
shows highly significant asymmetry, p < 0.0001, with six variants of
Egger's test all showing p < 0.0564-71.
Note that these tests fail even though treatment delay is uniformly
distributed. In reality treatment delay is more complex — each trial has
a different distribution of delays across patients, and the distribution
across trials may be biased (e.g., late treatment trials may be more common).
Similarly, many other variations in trials may produce asymmetry, including
dose, administration, duration of treatment, differences in SOC,
comorbidities, age, variants, and bias in design, implementation, analysis,
and reporting.
Figure 19. Example funnel plot analysis for simulated perfect trials.
Pharmaceutical drug
trials often have conflicts of interest whereby sponsors or trial staff have a
financial interest in the outcome being positive. UDCA for COVID-19
lacks this because it is off-patent, has multiple manufacturers, and is very low cost.
In contrast, most COVID-19 ursodeoxycholic acid trials have been run by
physicians on the front lines with the primary goal of finding the best
methods to save human lives and minimize the collateral damage caused by
COVID-19. While pharmaceutical companies are careful to run trials under
optimal conditions (for example, restricting patients to those most likely to
benefit, only including patients that can be treated soon after onset when
necessary, and ensuring accurate dosing), not all ursodeoxycholic acid trials
represent the optimal conditions for efficacy.
Summary statistics from
meta analysis necessarily lose information. As with all meta analyses, studies
are heterogeneous, with differences
in treatment delay, treatment regimen, patient demographics, variants,
conflicts of interest, standard of care, and other factors. We provide analyses for specific
outcomes and by treatment delay, and we aim to identify key characteristics in
the forest plots and summaries. Results should be viewed in the context of
study characteristics.
Some analyses classify treatment based on early or late
administration, as done here, while others distinguish between mild, moderate,
and severe cases. Viral load does not indicate degree of symptoms — for
example patients may have a high viral load while being asymptomatic. With
regard to treatments that have antiviral properties, timing of treatment is
critical — late administration may be less helpful regardless of
severity.
Details of treatment delay per patient is often not available.
For example, a study may treat 90% of patients relatively early, but the
events driving the outcome may come from 10% of patients treated very late.
Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.
Comparison across treatments is confounded by differences in
the studies performed, for example dose, variants, and conflicts of interest.
Trials with conflicts of interest may use designs better suited to the
preferred outcome.
In some cases, the most serious outcome has very few events,
resulting in lower confidence results being used in pooled analysis, however
the method is simpler and more transparent. This is less critical as the
number of studies increases. Restriction to outcomes with sufficient power may
be beneficial in pooled analysis and improve accuracy when there are few
studies, however we maintain our pre-specified method to avoid any
retrospective changes.
Studies show that combinations of treatments can be highly
synergistic and may result in many times greater efficacy than individual
treatments alone47-58.
Therefore standard of care may be critical and benefits may diminish or
disappear if standard of care does not include certain treatments.
This real-time analysis is constantly updated based on
submissions. Accuracy benefits from widespread review and submission of
updates and corrections from reviewers. Less popular treatments may receive
fewer reviews.
No treatment or intervention is 100% available and
effective for all current and future variants. Efficacy may vary significantly
with different variants and within different populations. All treatments have
potential side effects. Propensity to experience side effects may be predicted
in advance by qualified physicians. We do not provide medical advice. Before
taking any medication, consult a qualified physician who can compare all
options, provide personalized advice, and provide details of risks and
benefits based on individual medical history and situations.
Yu et al. present another meta analysis for ursodeoxycholic acid, showing significant improvement for severity.
SARS-CoV-2 infection and replication involves a complex
interplay of 50+ host and viral proteins and other
factors18-24, providing many therapeutic
targets.
Over 8,000 compounds have been predicted to reduce COVID-19
risk25, either by directly
minimizing infection or replication, by supporting immune system function, or
by minimizing secondary complications.
Figure 20 shows an overview of the results for ursodeoxycholic acid
in the context of multiple COVID-19 treatments, and Figure 21 shows a plot
of efficacy vs. cost for COVID-19 treatments.
Loading..
Figure 20.
Scatter plot showing results within the context of multiple COVID-19 treatments.
Diamonds shows the results of random effects meta-analysis.
0.5% of 8,000+ proposed treatments show efficacy74.
Loading..
Loading..
Figure 21. Efficacy vs. cost for COVID-19 treatments.
Significantly lower risk is seen for progression, recovery, and cases. 12 studies from 11 independent teams in 4 countries show significant
benefit.
Meta analysis using the most serious outcome reported shows
20% [-2‑38%] lower risk, without reaching statistical significance. Results are similar for higher quality and peer-reviewed studies.
Yu et al. present another meta analysis for ursodeoxycholic acid, showing significant improvement for severity.
Retrospective study from two registries of 1,096 COVID-19 patients with chronic liver disease, including 31 treated with ursodeoxycholic acid (UDCA). Propensity score matching was used to compare outcomes between UDCA-treated and untreated patients. The analysis found that UDCA treatment was associated with reduced hospitalization, ICU admission, ventilation, and death from COVID-19. The authors suggest that UDCA may decrease susceptibility to SARS-CoV-2 infection by downregulating the host receptor ACE2 through inhibition of the farnesoid X receptor.
Authors also show that UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ; and that UDCA reduces the expression of ACE2 in the nasal epithelium in humans.
Authors also show that UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ; and that UDCA reduces the expression of ACE2 in the nasal epithelium in humans.
Retrospective cohort study of 10,147 chronic liver disease patients in France, with 1,322 exposed to ursodeoxycholic acid (UDCA), showing lower risk of hospitalization for COVID-19 with UDCA exposure, without statistical significance (adjusted OR 0.48, 95% CI 0.20-1.19). A case-control analysis of 88 hospitalized patients and 840 matched controls showed no significant difference, and there was no significant difference for ICU admission and mortality. The study is underpowered due to the low number of COVID-19 hospitalizations.
OpenSAFELY retrospective 11,305 primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) patients showing lower risk of COVID-19 hospitalization or death with ursodeoxycholic acid (UDCA) treatment.
Retrospective 215 patients with chronic hepatitis B in China, showing lower risk of COVID-19 infection, milder symptoms, and faster recovery with ursodeoxycholic acid (UDCA) treatment.
Retrospective 393 hospitalized patients with hematologic disorders in China, showing lower risk of COVID-19 with UDCA use.
Retrospective 3,214 veterans with cirrhosis comparing 1,607 participants taking ursodeoxycholic acid (UDCA) to 1,607 propensity score matched controls not taking UDCA. UDCA use was associated with significantly lower odds of SARS-CoV-2 infection, symptomatic COVID-19, moderate or worse COVID-19, and severe/critical COVID-19.
Retrospective 1,675,593 patients in the Jeonbuk CDM cohort and 8,528,533 patients in the NHIS cohort, showing ursodeoxycholic acid (UDCA) intake associated with significantly lower risk of COVID-19 infection and severe COVID-19.
Retrospective 1,040 outpatients in China showing lower COVID-19 cases, less severe symptoms, and shorter symptom duration with ursodeoxycholic acid (UDCA) use.
Retrospective propensity score matched cohort study of 225 chronic liver disease patients on UDCA therapy matched to 225 controls without UDCA in China. UDCA use was associated with lower COVID-19 infection rate (85% vs 94%), lower maximum temperature, less severe symptoms, shorter recovery time (5 vs 7 days median), and lower risk of infection on regression (OR 0.32). The results rely on patient self-report rather than lab confirmed COVID-19 diagnosis.
Retrospective 280 Chinese families with children previously seen in a liver clinic assessing whether ursodeoxycholic acid (UDCA) reduced SARS-CoV-2 infection risk. Among infected families, the study found no significant difference in confirmed or suspected SARS-CoV-2 infections between children taking UDCA (80.9%) and those not taking it (77.6%) (p=0.843).
PSM retrospective 629 hospitalized COVID-19 patients showing no significant difference in survival between 108 patients taking UDCA prior to infection compared to 521 matched controls not taking the drug. The lack of observed benefit in this retrospective inpatient cohort does not preclude potential protective effects of UDCA against infection or illness severe enough to require hospitalization.
Retrospective 8,964 primary care patients prescribed ursodeoxycholic acid (UDCA) in the UK. Higher categorized UDCA adherence (≥80%) was associated with lower COVID-19 incidence (OR 0.86), whereas adherence as a continuous variable was not significant. However, adherence was measured indirectly via prescription records which may not reflect actual usage. Additionally, more adherent patients may differ systematically on unmeasured confounders (e.g., health behaviors) that influence COVID-19 risk.
Retrospective 74,074 individuals with chronic liver disease in South Korea, showing lower risk of COVID-19 infection and related severe outcomes with ursodeoxycholic acid (UDCA) use. The risk reduction was dose-dependent, with greater benefits seen with higher UDCA exposure. Authors hypothesize that UDCA may reduce viral entry by downregulating the ACE2 receptor and modulate the cytokine storm implicated in severe COVID-19.
Retrospective cohort study of 9,617 patients with liver disease in Italy, divided into UDCA users and non-users. UDCA exposure was not associated with reduced SARS-CoV-2 infection or improved COVID-19 outcomes including death, hospitalization, and ICU admission in this unvaccinated cohort. The large sample size provides power, but administrative data limitations include lack of important confounders like BMI and hypertension.
Retrospective 94 outpatients attending a university hospital gastroenterology clinic in Japan showing no significant difference in SARS-CoV-2 infection rates between ursodeoxycholic acid (UDCA)-treated patients and control groups without UDCA treatment. However, UDCA-treated patients tended to have higher rates of subclinical infection based on serology, suggesting UDCA may reduce COVID-19 severity.
Retrospective 650,317 COVID-19 patients in Japan showing higher risk of severe COVID-19 with UDCA use. There may be significant residual confounding because authors do not appear to have adjusted for liver diseases (details of adjustments are not provided), and UDCA use is a strong indicator of certain liver conditions.
Retrospective 115 COVID-19 patients hospitalized during an Omicron outbreak in China, of which 65 received ursodeoxycholic acid (UDCA) treatment and 50 received standard care. It found that UDCA was associated with faster body temperature recovery, with a hazard ratio of 1.62 (95% CI 0.99-2.60, p=0.053) compared to standard care after adjusting for covariates. Patients receiving higher UDCA doses (≥300mg daily) had significantly faster recovery than the standard care group, with a hazard ratio of 1.82 (95% CI 1.07-3.10, p=0.028). To further analyze the exposure-response relationship, the authors developed an AI model called VirtualBody that accurately predicted individualized UDCA pharmacokinetic profiles. Additional analysis using VirtualBody-generated data found UDCA AUC, indicating total exposure over time, had a stronger correlation with clinical outcome than cumulative dose. Overall, the study suggests UDCA may shorten recovery time from COVID-19, especially at higher doses, warranting further investigation.
Retrospective 115 hospitalized COVID-19 patients in China showing faster time to body temperature recovery with ursodeoxycholic acid (UDCA) treatment. Results were better for higher dose treatment (300mg vs. 150mg).
Authors also perform a meta analysis showing lower risk of severe/critical COVID-19 with UDCA, which is listed separately1.
Authors also perform a meta analysis showing lower risk of severe/critical COVID-19 with UDCA, which is listed separately1.
Retrospective 167 severe COVID-19 patients showing lower mortality with ursodeoxycholic acid (UDCA). Timing and duration of treatment is unknown - UDCA patients may have been on UDCA since before COVID-19.
We perform ongoing searches of PubMed, medRxiv, Europe PMC,
ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research
Square, ScienceDirect, Oxford University Press, the reference lists of other
studies and meta-analyses, and submissions to the site c19early.org.
Search terms are ursodeoxycholic acid and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion.
All studies regarding the use of ursodeoxycholic acid for COVID-19 that report
a comparison with a control group are included in the main analysis.
Sensitivity analysis is performed, excluding studies with major issues,
epidemiological studies, and studies with minimal available information.
This is a living analysis and is updated regularly.
We extracted effect sizes and associated data from all studies.
If studies report multiple kinds of effects then the most serious
outcome is used in pooled analysis, while other outcomes are included in the
outcome specific analyses. For example, if effects for mortality and cases are
both reported, the effect for mortality is used, this may be different to the
effect that a study focused on.
If symptomatic
results are reported at multiple times, we used the latest time, for example
if mortality results are provided at 14 days and 28 days, the results at 28
days have preference. Mortality alone is preferred over combined outcomes.
Outcomes with zero events in both arms are not used, the next most serious
outcome with one or more events is used. For example, in low-risk populations
with no mortality, a reduction in mortality with treatment is not possible,
however a reduction in hospitalization, for example, is still valuable.
Clinical outcomes are considered more important than viral test status. When
basically all patients recover in both treatment and control groups,
preference for viral clearance and recovery is given to results mid-recovery
where available. After most or all patients have recovered there is little or
no room for an effective treatment to do better, however faster recovery is
valuable.
If only individual symptom data is available, the most serious symptom has
priority, for example difficulty breathing or low SpO2 is more
important than cough.
When results provide an odds ratio, we compute the relative risk when
possible, or convert to a relative risk according to75.
Reported confidence intervals and p-values were used when available,
using adjusted values when provided. If multiple types of adjustments are
reported propensity score matching and multivariable regression has preference
over propensity score matching or weighting, which has preference over
multivariable regression. Adjusted results have preference over unadjusted
results for a more serious outcome when the adjustments significantly alter
results. When needed, conversion between reported p-values and
confidence intervals followed Altman, Altman (B), and Fisher's exact
test was used to calculate p-values for event data. If continuity
correction for zero values is required, we use the reciprocal of the opposite
arm with the sum of the correction factors equal to 178.
Results are expressed with RR < 1.0 favoring treatment, and using the risk of
a negative outcome when applicable (for example, the risk of death rather than
the risk of survival). If studies only report relative continuous values such
as relative times, the ratio of the time for the treatment group versus the
time for the control group is used. Calculations are done in Python
(3.13.1) with
scipy (1.14.1), pythonmeta (1.26), numpy (1.26.4), statsmodels (0.14.4), and plotly (5.24.1).
Forest plots are computed using PythonMeta79
with the DerSimonian and Laird random effects model (the fixed effect
assumption is not plausible in this case) and inverse variance weighting.
Results are presented with 95% confidence intervals. Heterogeneity among studies was
assessed using the I2 statistic.
Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor
(4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome.
For all statistical tests, a p-value less than 0.05 was considered statistically significant.
Grobid 0.8.0 is used to parse PDF documents.
We have classified studies as early treatment if most patients
are not already at a severe stage at the time of treatment (for example based
on oxygen status or lung involvement), and treatment started within 5 days of
the onset of symptoms. If studies contain a mix of early treatment and late
treatment patients, we consider the treatment time of patients contributing
most to the events (for example, consider a study where most patients are
treated early but late treatment patients are included, and all mortality
events were observed with late treatment patients).
We note that a shorter time may be preferable. Antivirals are typically only
considered effective when used within a shorter timeframe, for example 0-36 or
0-48 hours for oseltamivir, with longer delays not being effective32,33.
We received no funding, this research is done in our spare
time. We have no affiliations with any pharmaceutical companies or political
parties.
A summary of study results is below. Please submit
updates and corrections at https://c19early.org/udcameta.html.
Effect extraction follows pre-specified rules as detailed above
and gives priority to more serious outcomes.
For pooled analyses, the first (most serious) outcome is used, which may
differ from the effect a paper focuses on.
Other outcomes are used in outcome specific analyses.
| Yu (B), 7/8/2024, retrospective, China, peer-reviewed, 12 authors, study period 10 December, 2022 - 30 December, 2022. | time to recovery, 38.7% lower, HR 0.61, p = 0.04, treatment 65, control 50, adjusted per study, inverted to make HR<1 favor treatment, multivariable, Cox proportional hazards. |
Effect extraction follows pre-specified rules as detailed above
and gives priority to more serious outcomes.
For pooled analyses, the first (most serious) outcome is used, which may
differ from the effect a paper focuses on.
Other outcomes are used in outcome specific analyses.
| Brevini, 12/5/2022, retrospective, United Kingdom, peer-reviewed, 80 authors. | risk of death, 94.4% lower, RR 0.06, p = 0.13, treatment 0 of 31 (0.0%), control 14 of 155 (9.0%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), propensity score matching. |
| risk of mechanical ventilation, 66.7% lower, RR 0.33, p = 0.48, treatment 1 of 31 (3.2%), control 15 of 155 (9.7%), NNT 16, propensity score matching. | |
| risk of ICU admission, 75.0% lower, RR 0.25, p = 0.21, treatment 1 of 31 (3.2%), control 20 of 155 (12.9%), NNT 10, propensity score matching. | |
| risk of hospitalization, 39.6% lower, RR 0.60, p = 0.03, treatment 11 of 31 (35.5%), control 91 of 155 (58.7%), NNT 4.3, propensity score matching. | |
| Corpechot, 1/19/2024, retrospective, France, peer-reviewed, 5 authors, study period 1 March, 2020 - 31 December, 2020. | risk of death, 54.0% higher, RR 1.54, p = 0.45, treatment 3 of 1,322 (0.2%), control 13 of 8,825 (0.1%). |
| risk of ICU admission, 19.1% lower, RR 0.81, p = 1.00, treatment 4 of 1,322 (0.3%), control 33 of 8,825 (0.4%), NNT 1401. | |
| risk of hospitalization, 40.2% lower, RR 0.60, p = 0.17, treatment 1,322, control 8,825, adjusted per study, combination of cohort and case control analyses. | |
| risk of hospitalization, 51.8% lower, RR 0.48, p = 0.11, treatment 6 of 1,322 (0.5%), control 80 of 8,825 (0.9%), NNT 221, adjusted per study, odds ratio converted to relative risk, multivariable. | |
| risk of hospitalization, 7.0% lower, OR 0.93, p = 0.92, treatment 7 of 88 (8.0%) cases, 58 of 840 (6.9%) controls, adjusted per study, case control OR. | |
| Costello, 12/13/2023, retrospective, United Kingdom, peer-reviewed, 19 authors, study period 1 March, 2020 - 31 December, 2022. | risk of death, 24.0% lower, HR 0.76, p = 0.13, treatment 7,225, control 4,080. |
| risk of hospitalization, 19.0% lower, HR 0.81, p = 0.02, treatment 7,225, control 4,080. | |
| risk of death/hospitalization, 21.0% lower, HR 0.79, p = 0.005, treatment 7,225, control 4,080. | |
| Cui, 3/20/2024, retrospective, China, peer-reviewed, 5 authors. | recovery time >7 days, 47.8% lower, RR 0.52, p = 0.010, treatment 13 of 64 (20.3%), control 51 of 131 (38.9%), NNT 5.4, propensity score matching. |
| risk of case, 83.0% lower, OR 0.17, p = 0.001, treatment 78, control 137, adjusted per study, propensity score matching, multivariable, RR approximated with OR. | |
| Gao, 11/28/2023, retrospective, China, peer-reviewed, 5 authors, study period December 2022 - January 2023. | risk of case, 12.1% lower, RR 0.88, p = 0.03, treatment 114 of 163 (69.9%), control 183 of 230 (79.6%), NNT 10, odds ratio converted to relative risk. |
| John, 4/5/2023, retrospective, USA, peer-reviewed, 15 authors. | risk of death, 42.0% lower, OR 0.58, p = 0.28, treatment 1,607, control 1,607, adjusted per study, propensity score matching, multivariable, RR approximated with OR. |
| risk of severe case, 54.0% lower, OR 0.46, p = 0.03, treatment 1,607, control 1,607, adjusted per study, propensity score matching, multivariable, RR approximated with OR. | |
| risk of moderate/severe case, 55.0% lower, OR 0.45, p = 0.002, treatment 1,607, control 1,607, adjusted per study, propensity score matching, multivariable, RR approximated with OR. | |
| risk of symptomatic case, 50.0% lower, OR 0.50, p < 0.001, treatment 1,607, control 1,607, adjusted per study, propensity score matching, multivariable, RR approximated with OR. | |
| risk of case, 48.0% lower, OR 0.52, p < 0.001, treatment 1,607, control 1,607, adjusted per study, propensity score matching, multivariable, RR approximated with OR. | |
| Lee (B), 8/14/2024, retrospective, South Korea, peer-reviewed, 14 authors. | risk of severe case, 57.2% lower, HR 0.43, p = 0.19, treatment 2,934, control 2,934, adjusted per study, combined. |
| risk of severe case, 79.0% lower, HR 0.21, p < 0.001, treatment 414, control 414, adjusted per study, propensity score matching, multivariable, Cox proportional hazards. | |
| risk of severe case, 23.0% lower, HR 0.77, p = 0.02, treatment 2,934, control 2,934, adjusted per study, propensity score matching, multivariable, Cox proportional hazards. | |
| risk of case, 14.8% lower, HR 0.85, p = 0.21, adjusted per study, combined. | |
| risk of case, 29.0% lower, HR 0.71, p = 0.03, treatment 20,296, control 20,296, adjusted per study, propensity score matching, multivariable, Cox proportional hazards. | |
| risk of case, 7.0% lower, HR 0.93, p < 0.001, adjusted per study, propensity score matching, multivariable, Cox proportional hazards. | |
| Li, 7/31/2024, retrospective, China, peer-reviewed, median age 56.0, 21 authors, study period 1 July, 2022 - 31 December, 2022. | risk of symptomatic case, 21.2% lower, RR 0.79, p = 0.001, treatment 93 of 128 (72.7%), control 59 of 64 (92.2%), NNT 5.1, propensity score matching. |
| risk of case, 19.5% lower, RR 0.81, p = 0.004, treatment 95 of 128 (74.2%), control 59 of 64 (92.2%), NNT 5.6, propensity score matching. | |
| risk of progression, 18.2% lower, RR 0.82, p = 0.04, treatment 93, control 59, all symptoms combined. | |
| risk of progression, 18.4% lower, RR 0.82, p = 0.04, treatment 63 of 93 (67.7%), control 49 of 59 (83.1%), NNT 6.5, fever. | |
| risk of progression, 25.8% lower, RR 0.74, p = 0.01, treatment 55 of 93 (59.1%), control 47 of 59 (79.7%), NNT 4.9, cough. | |
| risk of progression, 57.2% lower, RR 0.43, p < 0.001, treatment 31 of 93 (33.3%), control 46 of 59 (78.0%), NNT 2.2, sore throat. | |
| risk of progression, 4.9% higher, RR 1.05, p = 0.87, treatment 43 of 93 (46.2%), control 26 of 59 (44.1%), muscle/joint pain. | |
| risk of progression, 17.8% lower, RR 0.82, p = 0.40, treatment 35 of 93 (37.6%), control 27 of 59 (45.8%), NNT 12, expectoration. | |
| risk of progression, 30.6% lower, RR 0.69, p = 0.06, treatment 35 of 93 (37.6%), control 32 of 59 (54.2%), NNT 6.0, fatigue. | |
| risk of progression, 34.3% higher, RR 1.34, p = 0.23, treatment 36 of 93 (38.7%), control 17 of 59 (28.8%), headache. | |
| risk of progression, 13.3% higher, RR 1.13, p = 0.71, treatment 25 of 93 (26.9%), control 14 of 59 (23.7%), anorexia. | |
| risk of progression, 10.1% lower, RR 0.90, p = 0.83, treatment 17 of 93 (18.3%), control 12 of 59 (20.3%), NNT 49, hyposthenia. | |
| risk of progression, 11.0% higher, RR 1.11, p = 1.00, treatment 14 of 93 (15.1%), control 8 of 59 (13.6%), runny nose. | |
| Li (B), 5/3/2023, retrospective, China, peer-reviewed, mean age 53.0, 5 authors, study period January 2022 - December 2022. | risk of hospitalization, 40.0% lower, RR 0.60, p = 0.72, treatment 3 of 225 (1.3%), control 5 of 225 (2.2%), NNT 112. |
| hospitalization time, 28.6% lower, relative time 0.71, p < 0.001, treatment median 5.0 IQR 3.0 n=225, control median 7.0 IQR 3.0 n=225. | |
| risk of severe case, 80.0% lower, RR 0.20, p = 0.22, treatment 1 of 225 (0.4%), control 5 of 225 (2.2%), NNT 56. | |
| risk of moderate/severe case, 80.0% lower, RR 0.20, p < 0.001, treatment 10 of 225 (4.4%), control 50 of 225 (22.2%), NNT 5.6. | |
| risk of case, 10.9% lower, RR 0.89, p = 0.05, treatment 192 of 225 (85.3%), control 212 of 225 (94.2%), NNT 11, odds ratio converted to relative risk, propensity score matching. | |
| Liu, 6/29/2023, retrospective, China, peer-reviewed, survey, 2 authors. | risk of case, 2.1% higher, RR 1.02, p = 0.88, treatment 95 of 146 (65.1%), control 51 of 80 (63.7%), confirmed. |
| risk of case, 4.3% higher, RR 1.04, p = 0.61, treatment 118 of 146 (80.8%), control 62 of 80 (77.5%), confirmed + suspected. | |
| Marrone, 9/21/2023, retrospective, Italy, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 December, 2022. | risk of death, 7.0% higher, HR 1.07, p = 0.77, treatment 26 of 108 (24.1%), control 118 of 521 (22.6%), adjusted per study, multivariable, Cox proportional hazards. |
| Ming, 11/16/2023, retrospective, United Kingdom, peer-reviewed, 3 authors, high vs. low. | risk of case, 12.9% lower, RR 0.87, p = 0.03, treatment 185 of 3,804 (4.9%), control 297 of 5,060 (5.9%), NNT 99, odds ratio converted to relative risk, high vs. low adherence. |
| Moon, 8/27/2024, retrospective, South Korea, peer-reviewed, 6 authors, study period 1 January, 2021 - 31 December, 2021. | risk of severe case, 33.0% lower, OR 0.67, p = 0.04, treatment 63 of 733 (8.6%) cases, 88 of 733 (12.0%) controls, NNT 11, case control OR, propensity score matching. |
| risk of case, 20.0% lower, OR 0.80, p < 0.001, treatment 4,082 of 37,037 (11.0%) cases, 4,752 of 37,037 (12.8%) controls, NNT 23, case control OR, propensity score matching. | |
| Ojeda‐Fernández, 8/22/2023, retrospective, Italy, peer-reviewed, 11 authors, study period 1 March, 2020 - 31 May, 2021, trial NCT05659654 (history). | risk of death, 7.0% higher, HR 1.07, p = 0.67, treatment 54 of 219 (24.7%), control 259 of 1,141 (22.7%), adjusted per study, multivariable, Cox proportional hazards. |
| risk of ICU admission, 4.0% lower, HR 0.96, p = 0.96, treatment 3 of 219 (1.4%), control 15 of 1,141 (1.3%), adjusted per study, multivariable, Cox proportional hazards. | |
| risk of hospitalization, 6.0% higher, HR 1.06, p = 0.66, treatment 77 of 219 (35.2%), control 393 of 1,141 (34.4%), adjusted per study, multivariable, Cox proportional hazards. | |
| risk of case, 2.8% lower, OR 0.97, p = 0.77, wave 1 and wave 2 combined, RR approximated with OR. | |
| risk of case, 0.9% higher, RR 1.01, p = 0.94, treatment 83 of 1,687 (4.9%), control 399 of 7,930 (5.0%), NNT 896, odds ratio converted to relative risk, wave 1. | |
| risk of case, 8.7% lower, RR 0.91, p = 0.56, treatment 43 of 1,125 (3.8%), control 273 of 6,731 (4.1%), NNT 428, odds ratio converted to relative risk, wave 2. | |
| Okushin, 7/27/2023, retrospective, Japan, peer-reviewed, 7 authors, study period 1 January, 2023 - 10 February, 2023. | risk of symptomatic case, 16.7% lower, RR 0.83, p = 0.81, treatment 10 of 47 (21.3%), control 12 of 47 (25.5%), NNT 24, viral hepatitis, propensity score matching. |
| risk of case, no change, RR 1.00, p = 1.00, treatment 16 of 47 (34.0%), control 16 of 47 (34.0%), viral hepatitis, propensity score matching. | |
| risk of symptomatic case, no change, RR 1.00, p = 1.00, treatment 10 of 47 (21.3%), control 10 of 47 (21.3%), all, propensity score matching. | |
| risk of case, 6.7% higher, RR 1.07, p = 1.00, treatment 16 of 47 (34.0%), control 15 of 47 (31.9%), all, propensity score matching. | |
| Sakamaki, 9/27/2024, retrospective, Japan, peer-reviewed, mean age 52.1, 3 authors, study period 15 January, 2020 - 31 December, 2022, excluded in exclusion analyses: significant unadjusted confounding possible. | risk of severe case, 79.0% higher, OR 1.79, p < 0.001, adjusted per study, multivariable, RR approximated with OR. |
| Yu (C), 5/4/2023, retrospective, China, preprint, 11 authors, study period 10 December, 2022 - 30 December, 2022. | risk of no recovery, 38.3% lower, HR 0.62, p = 0.05, treatment 62, control 45, inverted to make HR<1 favor treatment. |
| Zheng, 6/22/2024, retrospective, China, peer-reviewed, 4 authors. | risk of death, 62.0% lower, OR 0.38, p = 0.03, treatment 42, control 125, adjusted per study, multivariable, RR approximated with OR. |
Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.
Yu et al., Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence, Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2024.2376153.
Rong et al., Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19, Cell Host & Microbe, doi:10.1016/j.chom.2024.11.007.
Yang et al., SARS-CoV-2 infection causes dopaminergic neuron senescence, Cell Stem Cell, doi:10.1016/j.stem.2023.12.012.
Scardua-Silva et al., Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19, Scientific Reports, doi:10.1038/s41598-024-52005-7.
Hampshire et al., Cognition and Memory after Covid-19 in a Large Community Sample, New England Journal of Medicine, doi:10.1056/NEJMoa2311330.
Duloquin et al., Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2, Journal of Clinical Medicine, doi:10.3390/jcm13051397.
Sodagar et al., Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches, Biomolecules, doi:10.3390/biom12070971.
Sagar et al., COVID-19-associated cerebral microbleeds in the general population, Brain Communications, doi:10.1093/braincomms/fcae127.
Verma et al., Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations, bioRxiv, doi:10.1101/2024.06.02.596989.
Panagea et al., Neurocognitive Impairment in Long COVID: A Systematic Review, Archives of Clinical Neuropsychology, doi:10.1093/arclin/acae042.
Ariza et al., COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations, Biomedicines, doi:10.3390/biomedicines12061147.
Vashisht et al., Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications, Viruses, doi:10.3390/v16081183.
Ahmad et al., Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium, The Neurohospitalist, doi:10.1177/19418744241292487.
Eberhardt et al., SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, Nature Cardiovascular Research, doi:10.1038/s44161-023-00336-5.
Van Tin et al., Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling, Cells, doi:10.3390/cells13161331.
Borka Balas et al., COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice, Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2405125.
AlTaweel et al., An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies, Archives of Microbiology & Immunology, doi:10.26502/ami.936500177.
Malone et al., Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
Murigneux et al., Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly, Nature Communications, doi:10.1038/s41467-024-44958-0.
Lv et al., Host proviral and antiviral factors for SARS-CoV-2, Virus Genes, doi:10.1007/s11262-021-01869-2.
Lui et al., Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling, Virology, doi:10.1128/mbio.00392-24.
Niarakis et al., Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859.
Katiyar et al., SARS-CoV-2 Assembly: Gaining Infectivity and Beyond, Viruses, doi:10.3390/v16111648.
Wu et al., Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition, RNA Biology, doi:10.1080/15476286.2024.2433830.
Tong et al., Ursodeoxycholic acid reduces ACE-2 activity in COVID-19 patients and Calu- 3 cells, Research Square, doi:10.21203/rs.3.rs-5317838/v1.
Lee et al., Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin‐converting enzyme 2, Pharmacology Research & Perspectives, doi:10.1002/prp2.1194.
Brevini et al., FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2, Nature, doi:10.1038/s41586-022-05594-0.
Zeraatkar et al., Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review, BMJ Medicine, doi:10.1136/bmjmed-2022-0003091.
Davidson et al., No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study, Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2023.08.011.
Sakamaki et al., Insights from a multicenter nationwide cohort analysis in Japan on the association of underlying conditions and pharmacological interventions with COVID-19 disease severity, Discover Public Health, doi:10.1186/s12982-024-00225-7.
Treanor et al., Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
McLean et al., Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.
Ikematsu et al., Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.
Hayden et al., Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.
Kumar et al., Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.
López-Medina et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2021.3071.
Korves et al., SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk, medRxiv, doi:10.1101/2024.03.08.24303818.
Faria et al., Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil, Science, doi:10.1126/science.abh2644.
Nonaka et al., SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.003.
Karita et al., Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection, medRxiv, doi:10.1101/2021.08.27.21262754.
Zavascki et al., Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil, Research Square, doi:10.21203/rs.3.rs-910467/v1.
Willett et al., The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism, medRxiv, doi:10.1101/2022.01.03.21268111.
Peacock et al., The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry, bioRxiv, doi:10.1101/2021.12.31.474653.
Williams, T., Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources, Do Your Own Research, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.
Xu et al., A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR, Rapid Communications in Mass Spectrometry, doi:10.1002/rcm.9358.
Jitobaom et al., Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2, Research Square, doi:10.21203/rs.3.rs-941811/v1.
Jitobaom (B) et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.
Jeffreys et al., Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.
Ostrov et al., Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells, Pathogens, doi:10.3390/pathogens10111514.
Alsaidi et al., Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model, Marine Drugs, doi:10.3390/md19080418.
Andreani et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.
De Forni et al., Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients, PLoS ONE, doi:10.1371/journal.pone.0276751.
Wan et al., Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level, Scientific Reports, doi:10.1038/s41598-024-54722-5.
Said et al., The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial, Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522.
Fiaschi et al., In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants, Viruses, doi:10.3390/v16020168.
Xing et al., Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals, Briefings in Bioinformatics, doi:10.1093/bib/bbab249.
Thairu et al., A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality, Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328.
Singh et al., The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae045.
Boulware, D., Comments regarding paper rejection, twitter.com/boulware_dr/status/1311331372884205570.
Rothstein, H., Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments, www.wiley.com/en-ae/Publication+Bias+in+Meta+Analysis:+Prevention,+Assessment+and+Adjustments-p-9780470870143.
Stanley et al., Meta-regression approximations to reduce publication selection bias, Research Synthesis Methods, doi:10.1002/jrsm.1095.
Rücker et al., Arcsine test for publication bias in meta-analyses with binary outcomes, Statistics in Medicine, doi:10.1002/sim.2971.
Peters, J., Comparison of Two Methods to Detect Publication Bias in Meta-analysis, JAMA, doi:10.1001/jama.295.6.676.
Moreno et al., Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study, BMC Medical Research Methodology, doi:10.1186/1471-2288-9-2.
Macaskill et al., A comparison of methods to detect publication bias in meta-analysis, Statistics in Medicine, doi:10.1002/sim.698.
Egger et al., Bias in meta-analysis detected by a simple, graphical test, BMJ, doi:10.1136/bmj.315.7109.629.
Harbord et al., A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints, Statistics in Medicine, doi:10.1002/sim.2380.
Huang et al., Bile acids and coronavirus disease 2019, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2024.02.011.
Fiorucci et al., Bile acids and bile acid activated receptors in the treatment of Covid-19, Biochemical Pharmacology, doi:10.1016/j.bcp.2023.115983.
Zhang et al., What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690.
Altman (B) et al., How to obtain the confidence interval from a P value, BMJ, doi:10.1136/bmj.d2090.
Sweeting et al., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Statistics in Medicine, doi:10.1002/sim.1761.
Yu (B) et al., Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence, Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2024.2376153.
Corpechot et al., Exploring the impact of ursodeoxycholic acid therapy on COVID‐19 in a real‐world setting, Journal of Medical Virology, doi:10.1002/jmv.29418.
Costello et al., Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform, Communications Medicine, doi:10.1038/s43856-024-00664-y.
Cui et al., Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B, Journal of Clinical Hepatology, doi:10.12449/JCH240309.
Gao et al., Effect of Ursodeoxycholic Acid for Sars-Cov-2 Prevention in Hematological Malignancies: An Observational Real-World Study, Blood, doi:10.1182/blood-2023-182862.
John et al., Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis, Journal of Internal Medicine, doi:10.1111/joim.13630.
Lee (B) et al., Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study, JMIR Public Health and Surveillance, doi:10.2196/59274.
Li et al., Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients, Frontiers in Pharmacology, doi:10.3389/fphar.2024.1381830.
Li (B) et al., Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1178590.
Liu et al., Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV‐2 infection in children, Liver International, doi:10.1111/liv.15660.
Marrone et al., Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 infection: A retrospective study of propensity score‐matched cohorts, Liver International, doi:10.1111/liv.15736.
Ming et al., A Retrospective Study in Patients With Varying Prescription Coverage With Ursodeoxycholic Acid and Association With Incidence of COVID-19 Diagnosis in Primary Care, Microbiology and Infectious Diseases The American Medical Journal, doi:10.33590/microbiolinfectdisamj/10304488.
Moon et al., Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea, Virology Journal, doi:10.1186/s12985-024-02464-1.
Ojeda‐Fernández et al., UDCA treatment against COVID‐19: Do we have enough clinical evidence for drug repurposing?, Journal of Internal Medicine, doi:10.1111/joim.13711.
Okushin et al., Ursodeoxycholic acid for coronavirus disease 2019 prevention, Journal of Internal Medicine, doi:10.1111/joim.13704.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.